---
document_datetime: 2024-07-29 12:34:07
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/teriflunomide-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: teriflunomide-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.4140293
conversion_datetime: 2025-12-20 19:03:25.2158
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Teriflunomide Accord

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                       | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                    |
|----------------------|-------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10135 /202309  | Periodic Safety Update EU Single assessment - teriflunomide | 30/05/2024                          | 26/07/2024                                  | SmPC and PL                      | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10135/202309. |
| X/0002               | Annex I_2.(c) Change or addition of a new strength/potency  | 22/02/2024                          | 19/04/2024                                  | SmPC, Annex II, Labelling        |                                                                                                                                            |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                         |            |            | and PL   |                        |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|------------------------|
| N/0004  | Minor change in labelling or package leaflet not (Art. 61.3 Notification)                                                                                                               | 15/04/2024 | 26/07/2024 | PL       | connected with the SPC |
| IB/0001 | B.III.1.a.1 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from an already approved manufacturer | 16/03/2023 | n/a        |          |                        |